Ewing sarcoma breakpoint region 1-Friend leukemia integration 1 transcription factor-DNA complex (EWS-FLI1–DNA complex)

The EWS-FLI1–DNA complex is the central oncogenic driver in Ewing sarcoma, a malignant small round blue cell tumor of the bone and soft tissue. It is formed by the EWS-FLI1 fusion protein, which results from a t(11;22)(q24;q12) chromosomal translocation that joins the Ewing sarcoma breakpoint region 1 (EWSR1) gene with the Friend leukemia integration 1 (FLI1) gene (Monument et al., 2014). This chimeric protein functions as an aberrant transcription factor, utilizing its FLI1-derived ETS domain to bind DNA at specific GGAA microsatellite response elements and its EWS-derived domain to recruit chromatin remodeling complexes (Riggi et al., 2014). These interactions lead to the massive dysregulation of the transcriptome, promoting cell proliferation and survival while inhibiting normal cellular differentiation. Therapeutic targeting of the complex is historically challenging due to the lack of traditional enzymatic pockets, but modern strategies include small molecules like TK-216 that disrupt protein-protein interactions with co-regulators like RNA Helicase A (Erkizan et al., 2009). Other approaches utilize DNA-binding agents like Mithramycin A to displace the fusion protein from its target promoters (Grohar et al., 2011). Because the EWS-FLI1 fusion is unique to tumor cells, the complex represents a highly specific target for precision oncology.

Other names

EWSR1-FLI1-DNA complexEWS-FLI1 fusion protein-DNA complexEWS-FLI1-GGAA microsatellite complexEWS-FLI1-RHA-DNA complex

Disruption of the interaction between the EWS-FLI1 fusion protein and its transcriptional co-regulators (such as RNA Helicase A) or direct interference with the protein's binding to DNA response elements, specifically GGAA microsatellites.